Syndicated Research Studies

The global clinical trials market was valued at USD 80.7 billion in 2023 and is projected to reach USD 123.5 billion by 2030, registering a compound annual growth rate (CAGR) of 6.49% between 2024 and 2030. The surge in market growth during 2020 was primarily driven by the COVID-19 pandemic. This uptick was evident across both traditional and virtual clinical trials. Many companies significantly increased investments in innovative drug development to help reduce the burden of COVID-19. For example, in 2020, Synairgen plc partnered with Parexel to conduct a Phase III trial evaluating Interferon-beta (IFN-beta) as a potential COVID-19 treatment. Several factors are expected to continue fueling market growth, including rapid technological advancements, increasing prevalence of chronic illnesses, globalization of clinical trial operations, greater integration of personalized medicine, and a growing reliance on contract research organizations (CROs). The COVID-19 pandemic also led to majo...

Clinical Trials Market Growth & Trends The global  clinical trials market  size is expected to reach USD 78.3 billion by 2030, registering a CAGR of 5.8% during the forecast period, according to a new report by Grand View Research, Inc. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and products. The market witnessed a decline of 6% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. In addition, clinical trials have become increasingly costly, adding to the overall cost of developing a drug. Clinical Trials Market Segmentation Grand View Research has segmented the global clinical trials market based on phase, study design, indication, indication by study design, sponsor, service type and region: Based on the Phase Insights, the market is segmented into Phase I, Phase II, Phase III, Phase IV. The Phase III segment acco...